1. Introduction {#sec1-jcm-09-00652}
===============

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended after percutaneous coronary intervention (PCI) to reduce stent thrombosis (ST) and ischemic events \[[@B1-jcm-09-00652]\]. However, the ideal duration of DAPT after stenting is still debatable. Longer usage of DAPT reduces the risk of ischemic events but increases the risk of bleeding events. Thus, there is a fundamental trade-off between ischemic risk and bleeding risk that needs to be considered while deciding the duration of DAPT \[[@B2-jcm-09-00652]\]. Meanwhile, owing to the advances in current devices, including new generation stents, the minimum DAPT duration required to avoid stent-associated ischemic outcomes is decreasing.

Recently, the Academic Research Consortium (ARC) has published a white paper to define high bleeding risk (HBR) stressing the careful usage of DAPT in patients undergoing PCI \[[@B3-jcm-09-00652]\]. Because more and more candidates for PCI are at high risk of bleeding, it is not surprising that various clinical trials, including the LEADERS FREE trial and the ONYX ONE trial, are being conducted to confirm the safety of a shorter duration of DAPT in patients with HBR \[[@B4-jcm-09-00652],[@B5-jcm-09-00652]\].

Ethnicity, in particular the East Asian ethnicity, may be a factor that contributes to higher bleeding risk. We, among others, have reported that East Asians may have higher rates of bleeding but have comparable or lower rates of ischemic events than Caucasian patients \[[@B6-jcm-09-00652],[@B7-jcm-09-00652],[@B8-jcm-09-00652],[@B9-jcm-09-00652]\]. However, there is a paucity of studies about the effect of ethnicity of the ischemia/bleeding risk.

Therefore, in the current study, we performed a meta-analysis to compare the differences in the efficacy and safety of a short course of DAPT among East Asians and non--East Asians to add to the evidence on the relationship between ethnicity and duration of DAPT.

2. Materials and Methods {#sec2-jcm-09-00652}
========================

2.1. Data Sources and Study Strategy {#sec2dot1-jcm-09-00652}
------------------------------------

We searched Pubmed, Embase, Cochrane library, and relevant websites to search for randomized clinical trials (RCT) assessing the clinical impact of long term DAPT (L-DAPT) and short-term DAPT (S-DAPT). The following search terms were used (("aspirin" AND "P2Y12 receptor inhibitor" or "clopidogrel" or "Plavix" or "prasugrel" or "Effient" or "ticagrelor" or "Brilinta" or "thienopyridine") or "DAPT" or "dual antiplatelet therapy") AND ("drug eluting stent" or "DES"). Search strategies included both the Medical Subject Heading term and text word searches. To ensure a comprehensive search of the literature, we also manually searched the reference lists of the included studies, recent reviews, editorials, and meta-analyses. No language restrictions were applied.

2.2. Study Selection, Data Extraction and Quality Assessment {#sec2dot2-jcm-09-00652}
------------------------------------------------------------

All the RCTs comparing different duration of DAPT after PCI were included in the meta-analysis. Two investigators independently reviewed the studies and extracted the results in a formalized dataset. Discrepancies were resolved by consensus by group discussion. The quality of the eligible RCTs was assessed using the Cochrane Collaboration's tool for assessing the risk of bias for RCTs. The search period took place form October 2008 to October 2018.

2.3. Outcomes and Definitions {#sec2dot3-jcm-09-00652}
-----------------------------

Study groups were classified as S-DAPT and L-DAPT. S-DAPT was defined as the per protocol shorter duration of DAPT after stent insertion. L-DAPT refers to the group using DAPT longer duration in each study. The primary endpoint was a composite of death, cardiac death, myocardial infarction (MI), stroke, revascularization or bleeding events, but the exact definition was different for each study. The ischemic outcome was defined as composite of cardiac death, MI, ST, stroke or revascularization. Additional outcomes included each components of primary outcome or ischemic outcome, and bleeding event. The exact definition of the primary, ischemic, and bleeding outcomes of each study was described in [Table 1](#jcm-09-00652-t001){ref-type="table"}.

2.4. Statistical Analysis {#sec2dot4-jcm-09-00652}
-------------------------

A random-effects model and fixed effect model with inverse variance weighting were used to calculate odds ratio (OR) and 95% confidence interval (CI), associated with S-DAPT versus L-DAPT for above end point. Forest plot was used to calculate the overall effect of studies. Heterogeneity between studies was assessed using Cochrane's Q test and I^2^ statistic, which denotes the percentage of total variation across study that is a result of heterogeneity rather than chance. I^2^ represents an estimate of the degree of inconsistency among studies, with scores of 25%, 50%, and 75% representing, respectively, low, moderate, or high inconsistency. Heterogeneity considered significant if the *p* value was less than 0.05. Funnel plots, Begg's test, and Egger's test were used to assess the publication bias. Analyses were performed with R programming language, version 3.5.0 (R Foundation for Statistical Computing, Vienne, Austria). The PRISMA statement for reporting systematic reviews and meta-analyses of studies was used for the method of the present study.

3. Results {#sec3-jcm-09-00652}
==========

3.1. Study Outlines and Characteristics {#sec3dot1-jcm-09-00652}
---------------------------------------

We initially identified 1670 publications by electronic search and on initial screening. After careful assessment of titles and abstracts, 136 studies were identified for review of full-text manuscripts. By full-text review, 123 studies were excluded mainly because of the non-randomized study design and short follow-up period. Finally, 13 studies were selected for our meta-analysis ([Figure 1](#jcm-09-00652-f001){ref-type="fig"}). Among these, the EXCELLENT \[[@B10-jcm-09-00652]\], RESET \[[@B11-jcm-09-00652]\], DES-LATE \[[@B12-jcm-09-00652]\], IVUS-XPL \[[@B13-jcm-09-00652]\], and NIPPON \[[@B14-jcm-09-00652]\] studies were conducted in East Asian countries (13,312 patients), while the PRODIGY \[[@B15-jcm-09-00652]\], OPTIMIZE \[[@B16-jcm-09-00652]\], ARCTIC INT \[[@B17-jcm-09-00652]\], DAPT \[[@B18-jcm-09-00652]\], SECURITY \[[@B19-jcm-09-00652]\], ISAR-SAFE \[[@B20-jcm-09-00652]\], ITALIC \[[@B21-jcm-09-00652]\], and OPTIDUAL \[[@B22-jcm-09-00652]\] were trials performed in non--East Asian countries (24,943 patients). The baseline characteristics of the study are listed in [Table 2](#jcm-09-00652-t002){ref-type="table"}. Among 38,255 patients, 19,054 and 19,201 patients were randomized to S-DAPT and L-DAPT groups, respectively. Descriptors of the included studies and baseline characteristics of the patients enrolled in these studies are provided in [Table 2](#jcm-09-00652-t002){ref-type="table"}.

3.2. Clinical Outcomes {#sec3dot2-jcm-09-00652}
----------------------

The rate of the primary analysis outcome was 4.1% (1555 events in 38,255 patients) in the total population. When stratified according to ethnicity and DAPT duration, the rate of the primary analysis outcome was similar between S-DAPT and L-DAPT (event rate 2.7% (180 of 6648 patients) vs. 2.6% (170 of 6664 patients)) among East Asians. Among non--East Asians, the event rate was 5.2% (647 of 12,406 patients) in the S-DAPT group, which was higher than that in the L-DAPT group (4.5%, 558 of 12,537 patients). The risk of occurrence of the primary outcome significantly increased in the S-DAPT compared with that in the L-DAPT among non--East Asians (S-DAPT vs. L-DAPT, OR = 1.16, 95% CI: 1.02--1.32, *p* = 0.02), but not among East Asians (S-DAPT vs. L-DAPT, OR = 1.06, 95% CI: 0.86--1.31, *p* = 0.58) ([Figure 2](#jcm-09-00652-f002){ref-type="fig"}). The funnel plot, Begg's test, and Egger's test did not reveal any publication bias (Begg's test *p* = 0.4354, Egger's test *p* = 0.1843) ([Supplementary Materials, Figure S1](#app1-jcm-09-00652){ref-type="app"}).

We analyzed the effect of DAPT on ischemic outcomes defined as a composite of cardiac death, MI, ST, stroke or revascularization according to ethnicity. Among non--East Asians, ischemic events occurred in 523 of 12,406 patients (4.2%) treated with S-DAPT and 429 of 12,537 patients (3.4%) treated with L-DAPT. Among East Asians, ischemic events occurred in 122 of 6,648 patients (1.8%) treated with S-DAPT and in 109 of 6,664 patients (1.6%) treated with L-DAPT. S-DAPT was associated with higher rates of ischemic events than L-DAPT among non--East Asians (S-DAPT vs. L-DAPT, OR = 1.24, 95% CI: 1.09--1.42, *p* \< 0.01), whereas L-DAPT was comparable to S-DAPT among East Asians (S-DAPT vs. L-DAPT, OR = 1.13, 95% CI: 0.86--1.47, p = 0.38; p for interaction 0.51) ([Figure 3](#jcm-09-00652-f003){ref-type="fig"}).

Other secondary endpoints, such as cardiac death was evaluated in 11 studies. No statistical difference in cardiac mortality was noted between the S-DAPT and L-DAPT groups among East Asians and non--East Asians. (S-DAPT vs. L-DAPT, OR = 0.77, 95% CI: 0.49--1.21, *p* = 0.26 in East Asians, OR = 1.04, 95% CI: 0.82--1.32, *p* = 0.76 in non--East Asians) ([Figure 4](#jcm-09-00652-f004){ref-type="fig"}). For MI, which was evaluated in 13 studies, L-DAPT was associated with lower MI rates than S-DAPT among both East Asians and non--East Asians; however it was statistically significant among non--East Asians. (S-DAPT vs. L-DAPT, OR = 1.51, 95% CI: 0.95--2.39, *p* = 0.08 in East Asians, OR = 1.32, 95% CI: 1.01--1.73, *p* = 0.04 in non--East Asians). No significant interaction was noted between East Asians and non--East Asians (*p* for interaction 0.62) ([Figure 5](#jcm-09-00652-f005){ref-type="fig"}). L-DAPT was associated with a lower risk of ST, which was slightly more pronounced in non--East Asians than in East Asians. (S-DAPT vs. L-DAPT, OR = 1.55, 95% CI: 0.77--3.09, *p* = 0.22 in East Asians, OR = 1.58, 95% CI: 0.92--2.70, *p* = 0.10 in non--East Asians; *p* for interaction 0.96) ([Figure 6](#jcm-09-00652-f006){ref-type="fig"}).

A total of 748 bleeding events (2.0%) occurred among the total population. When stratified based on the ethnicity and DAPT duration, bleeding events occurred in 0.7% (49 out of 6,648 patients) of patients treated with S-DAPT and in 1.1% (73 out of 6,664 patients) of patients treated with L-DAPT among the East Asian population. Among the non--East Asians, bleeding events occurred in 1.9% (228 out of 12,114 patients) of patients treated with S-DAPT and in 3.3% (398 of 12,227 patients) of patients treated with L-DAPT. S-DAPT significantly reduced the risk of bleeding events among both East Asians and non--East Asians (S-DAPT vs. L-DAPT, OR = 0.68, 95% CI: 0.47--0.97, *p* = 0.04 in East Asians, OR = 0.60, 95% CI: 0.48--0.76, *p* \< 0.01 in non--East Asians; *p* for interaction 0.59) ([Figure 7](#jcm-09-00652-f007){ref-type="fig"}).

4. Discussion {#sec4-jcm-09-00652}
=============

The current meta-analysis is the first study to compare the duration of DAPT from the racial standpoint. The main findings of this study are as follows: (1) L-DAPT showed a significantly lower rate of primary outcome among non--East Asians, whereas the effects of S-DAPT and L-DAPT were comparable among East Asians. (2) L-DAPT could significantly decrease ischemic outcomes among non--East Asians. (3) L-DAPT was associated with a lower risk of ST, which was slightly more prominent in non--East Asians than in East Asians. (4) S-DAPT decreased the risk of bleeding events in both ethnicities, compared to L-DAPT. Our meta-analysis intended to compare the bleeding/ischemic risk between East Asians and non--East Asians, suggesting that differences in ischemic/bleeding tendencies over the duration of DAPT are affected by ethnicity.

4.1. Ideal Duration of DAPT after PCI {#sec4dot1-jcm-09-00652}
-------------------------------------

Although there is no disagreement with using DAPT after PCI, the ideal duration of DAPT after stenting is debatable. Long-term use of DAPT is helpful for the prevention of late ST and ischemic events \[[@B1-jcm-09-00652],[@B23-jcm-09-00652]\], whereas this is associated with a higher bleeding risk. Thus, there is trade-off for deciding the duration of DAPT \[[@B2-jcm-09-00652]\].

The recommended minimum duration of DAPT has shortened with the emergence of several studies demonstrating the safety of short duration of DAPT. In the meta-analysis by Palmerini et al., three-month or six-month DAPT showed a similar rate of major adverse cardiovascular events and lower rate of bleeding compared with one-year DAPT \[[@B24-jcm-09-00652]\]. Similar results were observed in another meta-analysis \[[@B25-jcm-09-00652]\]. On the basis of these trials, the current guidelines recommend a varied and shorter DAPT duration \[[@B26-jcm-09-00652],[@B27-jcm-09-00652]\].

Currently it has been established that one size does not fit all for the usage of DAPT. Because many factors were proposed to influence the ischemic/bleeding tradeoff, the use of bleeding/ischemia scoring system (The DAPT score and PRECISE-DAPT score) to evaluate the benefits and risks of different DAPT durations recommended in the current guidelines \[[@B27-jcm-09-00652]\]. According to ARC HBR definition, patients are considered as HBR if at least one major or two minor criteria are met. Factors associated with an increased bleeding risk after PCI includes old age (≥75 years), renal disease, liver disease, active cancer, anemia, low platelet count, previous intracranial hemorrhage, stroke, brain arteriovenous malformation, bleeding diathesis, prior bleeding or transfusion history, long-term use of oral anticoagulation, non-steroidal anti-inflammatory drugs, or steroids, and recent trauma or surgery (3).

4.2. Effect of Ethnicity on DAPT Duration {#sec4dot2-jcm-09-00652}
-----------------------------------------

Among various factors that were suggested to affect the ischemic/bleeding tradeoff, the effect of ethnicity has not been fully evaluated. In particular, East Asians have been suggested to have higher bleeding risk and lower ischemic risk. There are some possible explanations of this trend.

First, East Asians have lower body mass index (BMI) than non--East Asians. Obesity is associated with a pro-thrombotic status. Overweight patients had higher levels of annexin V-micro particles, endothelial-derived, leukocyte-derived, and tissue factor-bearing micro particles than controls \[[@B28-jcm-09-00652]\].

Second, the differences in genetic polymorphism among the races may be related with differences in thrombogenicity. In the MESA (Multi-Ethnic Study of Atherosclerosis) study, differences are seen in the hemostatic factors and plasma endothelial marker levels \[[@B29-jcm-09-00652]\]. African-Americans generally had the most thrombogenic and dysfunctional endothelial profile (fibrinogen, factor VIII, D-dimer, plasmin-anti plasmin, and von Willebrand factor), followed by Hispanics and Caucasians, and then East Asians. East Asians had the highest levels of plasminogen activator inhibitors-1 than other races.

Thirdly, there are associations between inflammation and atherothrombosis. In the SWAN (Study of Women's Health across the Nation) study, the highest C-reactive protein (CRP) levels were found among African-American women, followed by Hispanics, Caucasians, and East Asians \[[@B30-jcm-09-00652]\].

Regarding clopidogrel, platelet inhibition is mediated by cytochrome P-450 isoenzymes (CYP) \[[@B31-jcm-09-00652]\]. Various mutations of CYP are related to a decrease in platelet responsiveness to clopidogrel, while many studies have shown a relationship between clopidogrel non-responsiveness and adverse clinical ischemic events \[[@B32-jcm-09-00652],[@B33-jcm-09-00652]\]. Asians are known to have a higher rate of CYP gene polymorphisms leading to a higher rate of clopidogrel non-responsiveness. Despite the previous results of clopidogrel non-responsiveness, moderate bleeding occurred more frequently among Asians than that among Caucasians, and ethnicity was an independent predictor of the moderate bleeding complications \[[@B34-jcm-09-00652]\]. This unique phenomenon among Asians was defined as the "East-Asian paradox," leading to a hypothesis that a different therapeutic window for platelet inhibition should be applied to Asians.

Moreover, following the improvement in coronary stents, the optimal duration of DAPT is reducing to decrease the bleeding risk while maintaining ischemic event prevention \[[@B2-jcm-09-00652]\]. In addition to the LEADERS FREE study, the ONYX ONE study also showed that Resolute Onyx DES was safe and effective for HBR patients with 1-month DAPT \[[@B4-jcm-09-00652],[@B5-jcm-09-00652]\]. Considering the current trend of reducing DAPT duration and differences in bleeding tendency according to ethnicity, the DAPT period may be reduced in East Asians.

4.3. Limitations {#sec4dot3-jcm-09-00652}
----------------

There are several limitations to this meta-analysis. First, the ethnicity was determined based on the sites of the participating studies. Although Caucasians are very rarely included in the RCTs on East Asians, we cannot exclude a small possibility of the ethnic mix-up in non-Asian studies. However, RCTs on both East Asians and non--East Asians are affected. Second, the difference effects of duration of DAPT seen may related to the difference of the East Asian and non--East Asian studies, rather than the racial differences. Therefore, caution is needed in interpreting the overall effect as the sole effect of racial difference. Third, each study used a different definition for S-DAPT and L-DAPT. However, because our study was planned to compare the relative effect of S-DAPT and L-DAPT and not to determine an optimal DAPT duration, we assume that this heterogeneity would not largely influence the results of our study. Fourth, most of these studies were underpowered to detect differences in outcomes because of the different study designs and lower event rates; while the primary endpoint definitions were heterogeneous between studies, we additionally analyzed the ischemic outcomes and bleeding outcomes, respectively to overcome this limitation.

5. Conclusions {#sec5-jcm-09-00652}
==============

Our data suggest that the ischemia/bleeding tradeoff and thus the therapeutic range of DAPT may be different between East Asians and non--East Asians. In the present analysis of RCTs, L-DAPT compared to S-DAPT showed significantly lower rate of ischemic outcomes only in non--East Asian, while bleeding events were decreased by S-DAPT in both ethnicities. These results suggest that the optimal duration of DAPT in East Asians could be shorter than that compared to non--East Asians.

The following are <https://www.mdpi.com/2077-0383/9/3/652/s1>, Figure S1: Assessment of publication bias using the funnel plot diagram for primary outcome.
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jcm-09-00652-t001_Table 1

###### 

Current large-scale randomized clinical trials (RCTs) comparing the efficacy and safety of long-term and short-term dual antiplatelet therapy (DAPT).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study        Study Performed Nation       Year   DAPT Duration and Patient Number   Trial Design      Primary Endpoint                   Ischemic Outcome                            Bleeding Outcomes        Result
  ------------ ---------------------------- ------ ---------------------------------- ----------------- ---------------------------------- ------------------------------------------- ------------------------ -----------------------------------------------------------------------
  EXCELLENT    East Asia\                   2012   6 months (*n* = 722)\              Non-inferiority   Cardiac death/MI\                  Cardiac death/MI\                           Any bleeding             Non-inferiority of 6 months DAPT demonstrated
               (Korea)                             12 months (*n* = 721)                                /Ischemia driven TVR               /Ischemia driven TVR                                                 

  PRODIGY      Europe                       2012   6 months (*n* = 751)\              Superiority       Death/MI/Stroke                    Cardiac death                               TIMI major or minor      Superiority of 24 months DAPT was not demonstrated
                                                   24 months (*n* = 750)                                                                                                                                        

  RESET        East Asia\                   2012   3 months (*n* = 1059)\             Non-inferiority   Cardiac death/MI/ST\               Cardiac death/MI                            TIMI major or minor      Non-inferiority of 3 months DAPT demonstrated
               (Korea)                             12 months (*n* = 1058)                               /TVR/Major bleeding                                                                                     

  OPTIMIZE     South America                2013   3 months (*n* = 1563)\             Non-inferiority   Death/MI/Stroke/\                  Cardiac death/MI/ST                         Any bleeding             Non-inferiority of 3 months DAPT demonstrated
                                                   12 months (*n* = 1556)                               Major bleeding                                                                                          

  ARCTIC INT   Europe                       2014   12 months (*n* = 624)\             Superiority       Death/MI/ST/Stroke/\               ST/urgent revascularization                 STEEPLE major or minor   Superiority of 24 months DAPT was not demonstrated
                                                   24 months (*n* = 635)                                urgent revascularization                                                                                

  DAPT         America, Australia, Europe   2014   12 months (*n* = 4941)\            Superiority       ST and All cause death/MI/Stroke   Death/MI/Stroke                             BARC 2, 3, or 5          Superiority of 30 months DAPT was demonstrated
                                                   30 months (*n* = 5020)                                                                                                                                       

  DES-LATE     East Asia\                   2014   12 months (*n* = 2514)\            Equivalence       Cardiac death/MI\                  Cardiac death/MI                            TIMI major bleeding      Equal effect of 12 months and 24 months DAPT
               (Korea)                             36 months (*n* = 2531)                               /Stroke                                                                                                 

  SECURITY     Europe                       2014   6 months (*n* = 682)\              Non-inferiority   Cardiac death/MI/ST/Stroke\        MI                                          BARC 2, 3, or 5          Non-inferiority of 6 months DAPT demonstrated
                                                   12 months (*n* = 717)                                /Major Bleeding                                                                                         

  ISAR-SAFE    Europe                       2015   6 months (*n* = 1997)\             Non-inferiority   Death/MI/ST/Stroke\                Death/MI/ST/Stroke                          TIMI major or minor      Non-inferiority of 6 months DAPT demonstrated (premature termination)
                                                   12 months (*n* = 2003)                               /Major bleeding                                                                                         

  ITALIC       Europe, Middle East          2015   6 months (*n* = 926)\              Non-inferiority   Death/MI/TVR\                      Death/MI/Stroke                             TIMI major or minor      Non-inferiority of 6 months DAPT demonstrated
                                                   24 months (*n* = 924)                                Stroke/Major bleeding                                                                                   

  IVUS-XPL     East Asia\                   2016   6 months (*n* = 699)\              Equivalence       Cardiac death/MI/\                 Cardiac death/MI/Repeat revascularization   TIMI major bleeding      Equal effect of 6 months and 12 months DAPT
               (Korea)                             12 months (*n* = 701)                                Stroke/Major bleeding                                                                                   

  OPTIDUAL     Europe                       2016   12 months (*n* = 690)\             Superiority       Death/MI/Stroke/\                  Death/MI/Stroke                             TIMI major or minor      Superiority of 48 months DAPT was not demonstrated
                                                   48 months (*n* = 695)                                Major bleeding                                                                                          

  NIPPON       East Asia\                   2017   6 months (*n* = 1886)\             Non-inferiority   Death/MI/Stroke/\                  Cardiac death                               BARC 3 or 5 bleeding     Non-inferiority of 6 months DAPT demonstrated
               (Japan)                             18 months (*n* = 1887)                               Major bleeding                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT, randomized controlled trials; DAPT, dual antiplatelet therapy; EXCELLENT, efficacy of Xience/Promus versus cypher to reduce late loss after stenting; MI, myocardial infarction; TVR, target vessel revascularization; PRODIGY, prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study; TIMI, thrombolysis in myocardial infarction; RESET, real safety and efficacy of three-month dual antiplatelet therapy following Endeavor zotarolimus-eluting stent implantation; ST, stent thrombosis; OPTIMIZE, optimized duration of clopidogrel therapy following treatment with the zotarolimus-eluting stent in real-world clinical practice; ARCTIC INT, dual-antiplatelet treatment beyond one year after drug-eluting stent implantation; STEEPLE, safety and efficacy of enoxaparin in percutaneous coronary intervention patients; DES-LATE, duration of clopidogrel therapy after drug-eluting stent; SECURITY, second generation drug-eluting stent implantation followed by six- versus 12-month antiplatelet therapy; ISAR-SAFE, safety and efficacy of six months dual antiplatelet therapy after drug-eluting stenting; ITALIC, is there a life for DES after discontinuation of clopidogrel; IVUS-XPL, impact of intravascular ultrasound guidance on outcomes of XIENCE PRIME stents in long lesions; OPTIDUAL, optimal dual antiplatelet therapy; NIPPON, Nobori dual antiplatelet therapy as appropriate duration.

jcm-09-00652-t002_Table 2

###### 

Baseline patient characteristics in the including studies.

  Study        N      Follow-up (Months)   Age (Years)   Male (%)     DM (%)       ACS (%)      Clopidogrel/Prasugrel/Ticagrelor   First Generation DES/Second Generation DES (%)   Prior MI (%)   Timing of Randomization
  ------------ ------ -------------------- ------------- ------------ ------------ ------------ ---------------------------------- ------------------------------------------------ -------------- -------------------------
  EXCELLENT    1443   12                   63            931 (65%)    550 (38%)    744 (52%)    100/0/0                            25/75                                            74 (5%)        Index PCI
  PRODIGY      1970   24                   68            1511 (77%)   477 (24%)    1465 (74%)   100/0/0                            25/50                                            528 (27%)      1 month
  RESET        2117   12                   62            1347 (64%)   621 (29%)    1156 (55%)   100/0/0                            NA                                               36 (2%)        Index PCI
  OPTIMIZE     3119   12                   62            1974 (63%)   1103 (35%)   996 (32%)    100/0/0                            0/100                                            1083 (35%)     Index PCI
  ARCTIC INT   1259   17                   64            1011 (80%)   420 (33%)    NA           91.4/8.6/0                         42/63                                            383 (30%)      12 months
  DAPT         9961   33                   62            7435 (75%)   3037 (30%)   4251 (43%)   65/35/0                            38/60                                            2118 (22%)     12 months
  DES-LATE     5045   36                   62            3498 (69%)   1418 (28%)   3063 (61%)   100/0/0                            64/36                                            195 (4%)       12 months
  SECURITY     1399   12                   65            1080 (77%)   429 (31%)    442 (32%)    99.4/0.2/0.4                       0/100                                            289 (21%)      Index PCI
  ISAR-SAFE    4000   15                   67            3223 (81%)   979 (24%)    1601 (40%)   100/0/0                            27/72                                            1007 (25%)     6 months
  ITALIC       1850   24                   62            1483 (80%)   685 (37%)    806 (44%)    98.2/0.1/1.7                       0/100                                            282 (15%)      6 months
  IVUS-XPL     1400   12                   64            964 (69%)    506 (36%)    686 (49%)    100/0/0                            0/100                                            63 (5%)        Index PCI
  OPTIDUAL     1385   34                   64            1115 (81%)   435 (31%)    501 (36%)    100/0/0                            34/66                                            241 (17%)      12 months
  NIPPON       3307   18                   67            2616 (79%)   1254 (38%)   1079 (33%)   97/0.1/0                           0/100                                            396 (12%)      Index PCI

DM, diabetes mellitus; ACS, acute coronary syndrome; DES, drug eluting stent; MI, myocardial infarction; EXCELLENT, efficacy of Xience/Promus versus cypher to reduce late loss after stenting; PCI, percutaneous coronary intervention; PRODIGY, prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study; RESET, real safety and efficacy of three-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation; OPTIMIZE, optimized duration of clopidogrel therapy following treatment with the Zotarolimus-eluting stent in real-world clinical practice; ARCTIC INT, dual-antiplatelet treatment beyond one year after drug-eluting stent implantation; NA, not accessible; DAPT, dual antiplatelet therapy; DES-LATE, duration of clopidogrel therapy after drug-eluting stent; SECURITY, second generation drug-eluting stent implantation followed by six- versus 12-month antiplatelet therapy; ISAR-SAFE, safety and efficacy of six months dual antiplatelet therapy after drug-eluting stenting; ITALIC, is there a life for DES after discontinuation of clopidogrel; IVUS-XPL, impact of intravascular ultrasound guidance on outcomes of XIENCE PRIME stents in long lesions; OPTIDUAL, optimal dual antiplatelet therapy; NIPPON, Nobori dual antiplatelet therapy as appropriate duration.
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